West Pharmaceutical Services has agreed to sell all manufacturing and supply rights for its SmartDose 3.5mL On-Body Delivery System, along with associated facilities, to AbbVie for $112.5 million at closing. The transaction is expected to close in mid-2026, subject to customary closing conditions, with the final price also subject to working capital and other adjustments.
Under the agreement, West will continue the commercial supply of the SmartDose 3.5mL system and carry out certain ongoing project execution commitments prior to closing. West also said the deal structure includes the potential for additional project payments tied to achieving milestones before the transaction closes.
West Chief Executive Officer Eric M. Green said the company decided to transition the SmartDose 3.5mL product to AbbVie following a portfolio review, positioning the move as consistent with West’s focus on its customer development pipeline and large-dose, patient-centric on-body delivery technologies.
West said SmartDose 3.5mL revenue is expected to represent about 4% of the company’s fiscal 2025 revenue. The company plans to provide additional detail when it issues 2026 guidance alongside its fourth-quarter 2025 earnings report, which it expects to hold in February.
West will continue developing and manufacturing other SmartDose formats, including its SmartDose 10mL On-Body Delivery System and adaptive technologies aimed at larger-volume delivery.
KEY QUOTES:
“West pioneered the innovation of the on-body delivery device technology for complex injectable medicines, which has improved the lives of people around the world. As part of our portfolio review, we have determined it is best to transition the SmartDose 3.5mL product to AbbVie. This decision aligns with our ongoing commitment to our customer development pipeline and patient-centric approach for large dose on-body delivery devices to drive durable and profitable growth.”
Eric M. Green, President, CEO and Chair, West Pharmaceutical Services
